Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that certain of its subsidiaries have entered into a new credit agreement providing the Company with a $150 million term loan facility and a $30 million revolving credit facility. Borrowings under the new term loan facility, together with approximately $98.5 million of cash on hand, were used to prepay outs.

Business Wire • Jun 3, 2026

Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable

Maravai LifeSciences Holdings, Inc. is upgraded to Buy, driven by operational restructuring, improved guidance, and sector recovery. MRVI raised 2026 revenue guidance to $205–$215M and adjusted EBITDA to $30–$32M, reflecting robust Q1 results and cost savings. TriLink segment showed 15% YoY growth; restructuring actions are delivering over $65M in annual EBITDA savings.

Seeking Alpha • May 18, 2026

Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that the Company will participate in the following investor conference in June. On June 4, 2026, at 12:50 p.m. Eastern Time, Raj Asarpota, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York City, NY. A live webcast of the fireside chat will be on th.

Business Wire • May 18, 2026

Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2026 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 10, 2026

Maravai LifeSciences Q1 Earnings Call Highlights

Maravai LifeSciences NASDAQ: MRVI reported first-quarter fiscal 2026 results that management said marked a “strong start to 2026,” driven by growth at its TriLink segment, steady contribution from Cygnus, and the impact of restructuring actions taken last year.

MarketBeat • May 8, 2026

Maravai LifeSciences Reports First Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2026, together with other business updates. Key Financial Results: Revenue of $65.8 million, Net loss of $(6.4) million, and Adjusted EBITDA of $20.3 million; Returned to positive free cash flow, generating $4.2 million in the quarter; and Inc.

Business Wire • May 7, 2026

Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates

Maravai LifeSciences Holdings, Inc. (MRVI) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to a loss of $0.08 per share a year ago.

Zacks Investment Research • May 7, 2026

All You Need to Know About Maravai LifeSciences (MRVI) Rating Upgrade to Buy

Maravai LifeSciences (MRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • May 6, 2026

Maravai LifeSciences To Host Earnings Conference Call on Thursday, May 7, 2026

SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2026 financial and operating results after the market close on Thursday, May 7, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-343-5172 or 1-203-518-9856 and reference Marava.

Business Wire • Apr 20, 2026

Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2025 Earnings Call Transcript

Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 26, 2026